Oslo, Norway, September 27, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today hosts its Capital Markets Day in
Oslo.
The presentation slides are available in the Investors section of the Company's
website at: https://nykode.com/investors/financial-reports-and-presentations/.
The archived webcast of last week's Capital Markets Day in New York, including
the presentation by Dr. Bradley Monk, VP and Member of the Board of Directors of
the GOG-Foundation, may be accessed on the following link:
https://event.webcasts.com/starthere.jsp?ei=1633969&tp_key=dc0959d03d
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on treatment
of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to APC, which have been shown to induce broad,
strong and long-lasting antigen specific immune responses which correlates with
clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer